Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 3
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a…
Hemolytic Disease of the Fetus and Newborn
Estimated
~$10 – $8,750
Janssen Research & Development, LLCNCT05912517
Global Prospective Hemolytic Disease of the Fetus and Newborn Registry
The purpose of this non-interventional study is to prospectively evaluate the risk of anemia (decreased red blood cells) in fetuses (baby before birth) and neo…
Hemolytic Disease of the Fetus and Newborn
Estimated
~$10 – $1,050
Janssen Research & Development, LLCNCT07194070